Wnt Signaling in Cancer: New Advances
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 20 December 2024 | Viewed by 1062
Special Issue Editor
Special Issue Information
Dear Colleagues,
Wnt signaling is one of the most fundamental signaling pathways in Metazoa. Depending on different combinations of ligands and receptors, the Wnt signaling transduction cascade can activate different pathways, which are categorized into two main groups: the canonical (or β-catenin-dependent) Wnt/β-catenin signaling pathway and the non-canonical (or β-catenin-independent) pathways, such as Wnt/Planar Cell Polarity (PCP) and Wnt/Calcium. These pathways regulate key aspects of embryonic development by controlling differentiation, proliferation, and migration. Their importance persists in adult life, where Wnt signaling acts as a stemness regulator. Due to its relevance, uncontrolled Wnt signaling is the driving force of multiple diseases, including cancer. Numerous malignant tumors have been described as modulated by Wnt signaling, such as Colorectal cancer, Breast cancer, Skin cancer, Pancreatic cancer, Liver cancer, and Leukemia, among others. Notably, several ongoing clinical trials target Wnt signaling pathway components, such as Porcupine inhibitors and an anti-DKK1 antibody. However, to date, there are no FDA-approved specific Wnt-targeting therapies.
In this Special Issue, we will focus on novel findings in the regulation of neoplasia through Wnt signaling, reviews detailing the relevance of this pathway to tumorigenesis, and the potential of targeting Wnt signaling as a therapeutic strategy to treat cancer.
I look forward to your contribution.
Dr. Danilo Predes
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Wnt signaling
- cancer
- colorectal cancer
- cancer stem cells
- stem cells
- small molecules
- oncogenesis
